Depression and diabetes: Treatment and health-care delivery

Frank Petrak, Harald Baumeister, Timothy C. Skinner, Alex Brown, Richard I.G. Holt

Research output: Contribution to journalReview article

51 Citations (Scopus)

Abstract

Despite research efforts in the past 20 years, scientific evidence about screening and treatment for depression in diabetes remains incomplete and is mostly focused on North American and European health-care systems. Validated instruments to detect depression in diabetes, although widely available, only become effective and thus recommended if subsequent treatment pathways are accessible, which is often not the case. Because of the well known adverse effects of the interaction between depression and diabetes, treatment goals should focus on the remission or improvement of depression as well as improvement in glycaemic control as a marker for subsequent diabetes outcome. Scientific evidence evaluating treatment for depression in type 1 and type 2 diabetes shows that depression can be treated with moderate success by various psychological and pharmacological interventions, which are often implemented through collaborative care and stepped-care approaches. The evidence for improved glycaemic control in the treatment of depression by use of selective serotonin reuptake inhibitors or psychological approaches is conflicting; only some analyses show small to moderate improvements in glycaemic control. More research is needed to evaluate treatment of different depression subtypes in people with diabetes, the cost-effectiveness of treatments, the use of health-care resources, the need to account for cultural differences and different health-care systems, and new treatment and prevention approaches.

LanguageEnglish
Pages472-485
Number of pages14
JournalThe Lancet Diabetes and Endocrinology
Volume3
Issue number6
DOIs
Publication statusPublished - 1 Jan 2015

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Petrak, Frank ; Baumeister, Harald ; Skinner, Timothy C. ; Brown, Alex ; Holt, Richard I.G. / Depression and diabetes : Treatment and health-care delivery. In: The Lancet Diabetes and Endocrinology. 2015 ; Vol. 3, No. 6. pp. 472-485.
@article{4106452505d54535a60816ccf0e130ec,
title = "Depression and diabetes: Treatment and health-care delivery",
abstract = "Despite research efforts in the past 20 years, scientific evidence about screening and treatment for depression in diabetes remains incomplete and is mostly focused on North American and European health-care systems. Validated instruments to detect depression in diabetes, although widely available, only become effective and thus recommended if subsequent treatment pathways are accessible, which is often not the case. Because of the well known adverse effects of the interaction between depression and diabetes, treatment goals should focus on the remission or improvement of depression as well as improvement in glycaemic control as a marker for subsequent diabetes outcome. Scientific evidence evaluating treatment for depression in type 1 and type 2 diabetes shows that depression can be treated with moderate success by various psychological and pharmacological interventions, which are often implemented through collaborative care and stepped-care approaches. The evidence for improved glycaemic control in the treatment of depression by use of selective serotonin reuptake inhibitors or psychological approaches is conflicting; only some analyses show small to moderate improvements in glycaemic control. More research is needed to evaluate treatment of different depression subtypes in people with diabetes, the cost-effectiveness of treatments, the use of health-care resources, the need to account for cultural differences and different health-care systems, and new treatment and prevention approaches.",
author = "Frank Petrak and Harald Baumeister and Skinner, {Timothy C.} and Alex Brown and Holt, {Richard I.G.}",
year = "2015",
month = "1",
day = "1",
doi = "10.1016/S2213-8587(15)00045-5",
language = "English",
volume = "3",
pages = "472--485",
journal = "The Lancet Diabetes and Endocrinology",
issn = "2213-8587",
publisher = "Elsevier BV",
number = "6",

}

Depression and diabetes : Treatment and health-care delivery. / Petrak, Frank; Baumeister, Harald; Skinner, Timothy C.; Brown, Alex; Holt, Richard I.G.

In: The Lancet Diabetes and Endocrinology, Vol. 3, No. 6, 01.01.2015, p. 472-485.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Depression and diabetes

T2 - The Lancet Diabetes and Endocrinology

AU - Petrak, Frank

AU - Baumeister, Harald

AU - Skinner, Timothy C.

AU - Brown, Alex

AU - Holt, Richard I.G.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Despite research efforts in the past 20 years, scientific evidence about screening and treatment for depression in diabetes remains incomplete and is mostly focused on North American and European health-care systems. Validated instruments to detect depression in diabetes, although widely available, only become effective and thus recommended if subsequent treatment pathways are accessible, which is often not the case. Because of the well known adverse effects of the interaction between depression and diabetes, treatment goals should focus on the remission or improvement of depression as well as improvement in glycaemic control as a marker for subsequent diabetes outcome. Scientific evidence evaluating treatment for depression in type 1 and type 2 diabetes shows that depression can be treated with moderate success by various psychological and pharmacological interventions, which are often implemented through collaborative care and stepped-care approaches. The evidence for improved glycaemic control in the treatment of depression by use of selective serotonin reuptake inhibitors or psychological approaches is conflicting; only some analyses show small to moderate improvements in glycaemic control. More research is needed to evaluate treatment of different depression subtypes in people with diabetes, the cost-effectiveness of treatments, the use of health-care resources, the need to account for cultural differences and different health-care systems, and new treatment and prevention approaches.

AB - Despite research efforts in the past 20 years, scientific evidence about screening and treatment for depression in diabetes remains incomplete and is mostly focused on North American and European health-care systems. Validated instruments to detect depression in diabetes, although widely available, only become effective and thus recommended if subsequent treatment pathways are accessible, which is often not the case. Because of the well known adverse effects of the interaction between depression and diabetes, treatment goals should focus on the remission or improvement of depression as well as improvement in glycaemic control as a marker for subsequent diabetes outcome. Scientific evidence evaluating treatment for depression in type 1 and type 2 diabetes shows that depression can be treated with moderate success by various psychological and pharmacological interventions, which are often implemented through collaborative care and stepped-care approaches. The evidence for improved glycaemic control in the treatment of depression by use of selective serotonin reuptake inhibitors or psychological approaches is conflicting; only some analyses show small to moderate improvements in glycaemic control. More research is needed to evaluate treatment of different depression subtypes in people with diabetes, the cost-effectiveness of treatments, the use of health-care resources, the need to account for cultural differences and different health-care systems, and new treatment and prevention approaches.

UR - http://www.scopus.com/inward/record.url?scp=84929956031&partnerID=8YFLogxK

U2 - 10.1016/S2213-8587(15)00045-5

DO - 10.1016/S2213-8587(15)00045-5

M3 - Review article

VL - 3

SP - 472

EP - 485

JO - The Lancet Diabetes and Endocrinology

JF - The Lancet Diabetes and Endocrinology

SN - 2213-8587

IS - 6

ER -